Pharma: Clinic Roundup
Tuesday, March 27, 2012
CSL Behring, of Charlotte, N.C., said the first patient was enrolled in the PATH (Polyneuropathy And Treatment with Hezentra) study to evaluate the safety and tolerability of two different doses of subcutaneous immunoglobulin compared to placebo in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.